Patents by Inventor Richard J. Samulski

Richard J. Samulski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPTIMIZED MINI-DYSTROPHIN GENES AND EXPRESSION CASSETTES AND THEIR USE
    Publication number: 20230398236
    Abstract: This invention relates to polynucleotides encoding mini-dystrophin proteins, viral vectors comprising the same, and methods of using the same for delivery of mini-dystrophin to a cell or a subject.
    Type: Application
    Filed: January 5, 2023
    Publication date: December 14, 2023
    Inventors: Xiao Xiao, Juan Li, Chunping Qiao, Scott W. J. McPhee, Richard J. Samulski, Maritza McIntyre
  • Optimized mini-dystrophin genes and expression cassettes and their use
    Patent number: 11547765
    Abstract: This invention relates to polynucleotides encoding mini-dystrophin proteins, viral vectors comprising the same, and methods of using the same for delivery of mini-dystrophin to a cell or a subject.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: January 10, 2023
    Assignees: The University of North Carolina at Chapel Hill, Bamboo Therapeutics, Inc.
    Inventors: Xiao Xiao, Juan Li, Chunping Qiao, Scott W. J. McPhee, Richard J. Samulski, Maritza McIntyre
  • MODIFIED SOLUBLE VEGF RECEPTOR-1 GENES AND VECTORS FOR GENE THERAPY
    Publication number: 20220389456
    Abstract: The present invention relates to a modified and optimized sFlt1 nucleic acid for inclusion in a virus vector. Use of such vectors can be used for treatment of ocular disorders causing neovascularization, such as macular degeneration.
    Type: Application
    Filed: July 1, 2022
    Publication date: December 8, 2022
    Applicant: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventor: Richard J. SAMULSKI
  • Modified soluble VEGF receptor-1 genes and vectors for gene therapy
    Patent number: 11414678
    Abstract: The present invention relates to a modified and optimized sFlt1 nucleic acid for inclusion in a virus vector. Use of such vectors can be used for treatment of ocular disorders causing neovascularization, such as macular degeneration.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: August 16, 2022
    Assignee: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventor: Richard J. Samulski
  • MODIFIED FRIEDREICH ATAXIA GENES AND VECTORS FOR GENE THERAPY
    Publication number: 20200384073
    Abstract: The present invention relates to a modified FXN gene providing for increased expression of the encoded protein frataxin that can be used for treatment of Friedreich ataxia.
    Type: Application
    Filed: December 16, 2019
    Publication date: December 10, 2020
    Inventor: Richard J. Samulski
  • OPTIMIZED MINI-DYSTROPHIN GENES AND EXPRESSION CASSETTES AND THEIR USE
    Publication number: 20200376141
    Abstract: This invention relates to polynucleotides encoding mini-dystrophin proteins, viral vectors comprising the same, and methods of using the same for delivery of mini-dystrophin to a cell or a subject.
    Type: Application
    Filed: February 11, 2020
    Publication date: December 3, 2020
    Inventors: Xiao Xiao, Juan Li, Chunping Qiao, Scott W.J. McPhee, Richard J. Samulski, Maritza McIntyre
  • Modified Friedreich ataxia genes and vectors for gene therapy
    Patent number: 10548947
    Abstract: The present invention relates to a modified FXN gene providing for increased expression of the encoded protein frataxin that can be used for treatment of Friedreich ataxia.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: February 4, 2020
    Assignee: Bamboo Therapeutics, Inc.
    Inventor: Richard J. Samulski
  • MODIFIED SOLUBLE VEGF RECEPTOR-1 GENES AND VECTORS FOR GENE THERAPY
    Publication number: 20190330308
    Abstract: The present invention relates to a modified and optimized sFlt1 nucleic acid for inclusion in a virus vector. Use of such vectors can be used for treatment of ocular disorders causing neovascularization, such as macular degeneration.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 31, 2019
    Inventor: Richard J. Samulski
  • Modified soluble VEGF receptor-1 genes and vectors for gene therapy
    Patent number: 10385112
    Abstract: The present invention relates to a modified and optimized sFlt1 nucleic acid for inclusion in a virus vector. Use of such vectors can be used for treatment of ocular disorders causing neovascularization, such as macular degeneration.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 20, 2019
    Assignee: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventor: Richard J. Samulski
  • OPTIMIZED MINI-DYSTROPHIN GENES AND EXPRESSION CASSETTES AND THEIR USE
    Publication number: 20170368198
    Abstract: This invention relates to polynucleotides encoding mini-dystrophin proteins, viral vectors comprising the same, and methods of using the same for delivery of mini-dystrophin to a cell or a subject.
    Type: Application
    Filed: June 20, 2017
    Publication date: December 28, 2017
    Inventors: Xiao Xiao, Juan Li, Chunping Qiao, Scott W.J. McPhee, Richard J. Samulski, Maritza Mclntyre
  • MODIFIED FRIEDREICH ATAXIA GENES AND VECTORS FOR GENE THERAPY
    Publication number: 20170128528
    Abstract: The present invention relates to a modified FXN gene providing for increased expression of the encoded protein frataxin that can be used for treatment of Friedreich ataxia.
    Type: Application
    Filed: November 1, 2016
    Publication date: May 11, 2017
    Inventor: Richard J. Samulski
  • Modified factor VIII and factor IX genes
    Patent number: 9506052
    Abstract: The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: November 29, 2016
    Assignee: Asklepios Biopharmaceutical, Inc.
    Inventor: Richard J. Samulski
  • MODIFIED SOLUBLE VEGF RECEPTOR-1 GENES AND VECTORS FOR GENE THERAPY
    Publication number: 20160009786
    Abstract: The present invention relates to a modified and optimized sFlt1 nucleic acid for inclusion in a virus vector. Use of such vectors can be used for treatment of ocular disorders causing neovascularization, such as macular degeneration.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 14, 2016
    Inventor: RICHARD J. SAMULSKI
  • MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY
    Publication number: 20140193880
    Abstract: The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 10, 2014
    Applicant: Asklepios Biopharmaceutical, Inc.
    Inventor: RICHARD J. SAMULSKI
  • Modified factor VIII and factor IX genes and vectors for gene therapy
    Patent number: 8632765
    Abstract: The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: January 21, 2014
    Assignee: Asklepios Biopharmaceuticals, Inc.
    Inventor: Richard J. Samulski
  • MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY
    Publication number: 20130004462
    Abstract: The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.
    Type: Application
    Filed: June 12, 2012
    Publication date: January 3, 2013
    Inventor: RICHARD J. SAMULSKI
  • Modified factor VIII and factor IX genes and vectors for gene therapy
    Patent number: 8198421
    Abstract: The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: June 12, 2012
    Assignee: Asklepios Biopharmaceutical, Inc.
    Inventor: Richard J. Samulski
  • MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY
    Publication number: 20100284971
    Abstract: The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.
    Type: Application
    Filed: June 19, 2007
    Publication date: November 11, 2010
    Applicant: ASKLEPIOS BIOPHARMACEUTICAL, INC.
    Inventor: Richard J. Samulski
  • Methods and Compositions for Regulated Expressions of Nucleic Acid at Post-Transcriptional Level
    Publication number: 20100196335
    Abstract: The present invention provides an isolated nucleic acid comprising: a) at least one first nucleotide sequence encoding a heterologous nucleotide sequence of interest; and b) at least two second heterologous nucleotide sequences, wherein each second heterologous nucleotide sequences comprises: i) a first set of splice elements defining a first intron that is removed by splicing to produce a first RNA molecule that imparts a biological function in the absence of activity at a second set of splice elements; and ii) the second set of splice elements defining one or more introns different from said first intron, wherein said one or more introns different from said first intron are removed by splicing to produce no RNA molecule and/or a second RNA molecule that docs not impart a biological function, when said second set of splice elements is active. Further provided are methods of using the nucleic acid of this invention to regulate transgene expression.
    Type: Application
    Filed: April 28, 2006
    Publication date: August 5, 2010
    Inventors: Richard J. Samulski, Kyson Xiaohuai Chou
  • AAV TRANSDUCTION OF MUSCLE TISSUE
    Publication number: 20090298922
    Abstract: A method of expressing a gene product in the muscle tissue of an animal, which comprises administering a recombinant AAV vector to the muscle tissue of the animal, wherein the vector comprises a non-AAV gene of interest ligated into an AAV vector genome.
    Type: Application
    Filed: August 7, 2009
    Publication date: December 3, 2009
    Inventors: Xiao Xiao, Richard J. Samulski, Juan Li